Patents by Inventor Peter M. Abadir

Peter M. Abadir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210389319
    Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodics are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 16, 2021
    Inventors: Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
  • Patent number: 10835516
    Abstract: Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT1R and AT2R receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: November 17, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Peter M. Abadir, Jeremy D. Walston
  • Patent number: 10835615
    Abstract: The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: November 17, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Honggang Cui, Jeremy D. Walston, Peter M. Abadir, Ran Lin
  • Publication number: 20200264173
    Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies arc identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
    Type: Application
    Filed: April 15, 2020
    Publication date: August 20, 2020
    Inventors: Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
  • Patent number: 10648977
    Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 12, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
  • Patent number: 10525144
    Abstract: The present invention provides compounds and a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction. The compounds include a mitochondrial targeting signal, a residue of a drug molecule, a functional moiety, and a scaffold moiety.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: January 7, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Honggang Cui, Peter M. Abadir, Jeremy D. Walston, Andrew G. Cheetham
  • Publication number: 20180306786
    Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
    Type: Application
    Filed: October 28, 2016
    Publication date: October 25, 2018
    Inventors: Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
  • Publication number: 20180289831
    Abstract: The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 11, 2018
    Inventors: Honggang Cui, Jeremy D. Walston, Peter M. Abadir, Lin Ran
  • Publication number: 20180289824
    Abstract: The present invention provides a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction.
    Type: Application
    Filed: November 10, 2015
    Publication date: October 11, 2018
    Inventors: Honggang Cui, Peter M. Abadir, Jeremy D. Walston, Andrew G. Cheetham
  • Publication number: 20160243080
    Abstract: Provided herein are pharmaceutical compositions for the treatment of wounds, including chronic wounds and diabetic ulcers. The pharmaceutical compositions, which comprise valsartan, inhibit angiotensin receptors in the wound bed. Also provided herein are methods of making the pharmaceutical compositions of the invention, and methods for treating wounds in patients in need thereof.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 25, 2016
    Inventors: Peter M. Abadir, Jeremy D. Walston
  • Publication number: 20150238465
    Abstract: Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT1R and AT2R receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.
    Type: Application
    Filed: January 15, 2015
    Publication date: August 27, 2015
    Applicant: The Johns Hopkins University
    Inventors: Peter M. Abadir, Jeremy D. Walston
  • Publication number: 20140057955
    Abstract: Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT1R and AT2R receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 27, 2014
    Applicant: The Johns Hopkins University
    Inventors: Peter M. Abadir, Jeremy D. Walston